Skip to main content
Fig. 5 | BMC Cancer

Fig. 5

From: Diverse mechanisms activate the PI 3-kinase/mTOR pathway in melanomas: implications for the use of PI 3-kinase inhibitors to overcome resistance to inhibitors of BRAF and MEK

Fig. 5

Efficacy of targeting PI3K in double-resistant cell lines. a Diagram of the development of double-resistant cell lines. NZM7PR and NZM20PR were maintained in increasing concentrations of ZSTK474 to create ZSTK474 resistant clones and tested for its sensitivity to the same as compared to its parental lines (b). Further the drug resistant clones were maintained in drug free media for at least 4 passages and re-challenged with drug in growth curve assay with ZSTK474 (c) and vemurafenib (d). All the data were a mean of 2 to 4 separate experiments carried out in duplicates. Data were from 3 to 4 independent experiments performed in duplicates

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us